Full history for every metric is available with a Kvantra account
Key financial summary
Financials in GBP| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | £bn | 9.9 | 9.5 | 10.9 | 11.3 | 11.2 | 11.0 | 11.2 | 11.4 |
| Operating profit | £bn | 2.48 | 2.38 | ||||||
| Net profit | £bn | 1.15 | 1.39 | 1.06 | 1.05 | 1.44 | 1.67 | 1.62 | 1.86 |
| EPS reported | £ | 0.19 | 0.18 | ||||||
| Operating cashflow per share | £ | 0.26 | 0.17 | ||||||
| Capex per share | £ | 0.04 | 0.04 | ||||||
| FCF per share | £ | 0.22 | 0.13 | ||||||
| Free cash flow | £bn | 2.02 | 1.19 | ||||||
| Net debt | £bn | 7.15 | 7.26 | ||||||
| Book value equity | £bn | 16.4 | 16.4 | ||||||
| Book value per share | £ | 1.82 | 1.84 | ||||||
| Number of shares | m | 9,010.81 | 8,920 | ||||||
| DPS (TTM paid) | £ | 0.07 | 0.07 |
Financial summary
Financials in GBP| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 19.73 | 19.29 | ||||||
| P/B LTM | x | 2.05 | 1.88 | ||||||
| P/S LTM | x | 3.05 | 2.76 | ||||||
| P/FCF LTM | x | 16.67 | 25.91 | ||||||
| EV/EBITDA LTM | x | 14.33 | 13.03 | ||||||
| EV/Sales LTM | x | 3.71 | 3.41 | ||||||
| Earnings Yield LTM | % | 5.07% | 5.18% | ||||||
| FCF Yield | % | 6.00% | 3.86% | ||||||
| Quality | |||||||||
| ROE | % | 10.15% | 9.89% | ||||||
| ROIC | % | 6.77% | 6.46% | ||||||
| Operating margin | % | 22.44% | 21.35% | ||||||
| Gross margin | % | 64.77% | 65.57% | ||||||
| FCF/Sales | % | 18.27% | 10.64% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +18.75% | +5.88% | ||||||
| Sales Growth YoY | % | -1.81% | +1.21% | ||||||
| Net Income Growth YoY | % | +15.60% | +6.64% | ||||||
| FCF Growth | % | +1.61% | +27.50% | ||||||
| Operating Profit Growth | % | +12.19% | +5.45% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 1.82% | 2.09% | ||||||
| Dividend Growth | % | +31.28% | +30.16% | ||||||
| Payout Ratio | % | 35.75% | 39.06% | ||||||
| FCF/Debt | x | 0.23 | 0.14 | ||||||
| Net Debt/EBITDA | x | 2.55 | 2.54 | ||||||
| EBIT/Net interest | x | 7.28 | 0.00 | ||||||
| Net debt/market cap | % | 21.29% | 23.61% | ||||||
| Net debt/Equity | x | 0.44 | 0.44 | ||||||
| Gross debt/equity | x | 0.52 | 0.50 | ||||||
ETFs that hold Haleon
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| VanEck Pharmaceutical ETF | PPH | 10 | 3.80% |
| Amundi MSCI UK IMI SRI Climate Paris Aligned UCITS ETF DR - GBP (C) | FTSE.PA | 1 | 4.95% |
| Harding Loevner International Developed Markets Select Equity ETF | LOEV | 10 | 3.08% |
Funds with Haleon among their ten largest holdings, largest fund first.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Haleon plc operates as a global entity focused on developing, manufacturing, and marketing an array of consumer health products. Its operations extend across multiple continents, specifically North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers a comprehensive selection of items, encompassing therapeutic oral care, pain relief solutions, respiratory health aids, digestive wellness products, as well as vitamins, minerals, and other dietary supplements. Prominent brands within its extensive portfolio include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The firm, incorporated in 2021, was initially named DRVW 2022 plc before rebranding to Haleon plc in February 2022. Its corporate headquarters are located in Brentford, United Kingdom.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| VanEck Pharmaceutical ETF | PPH | 10 | 3.80% |
| Amundi MSCI UK IMI SRI Climate Paris Aligned UCITS ETF DR - GBP (C) | FTSE.PA | 1 | 4.95% |
| Harding Loevner International Developed Markets Select Equity ETF | LOEV | 10 | 3.08% |
Funds with Haleon among their ten largest holdings, largest fund first.
Based on consensus from external analysts. Not Kvantra's opinion.
Haleon plc operates as a global entity focused on developing, manufacturing, and marketing an array of consumer health products. Its operations extend across multiple continents, specifically North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers a comprehensive selection of items, encompassing therapeutic oral care, pain relief solutions, respiratory health aids, digestive wellness products, as well as vitamins, minerals, and other dietary supplements. Prominent brands within its extensive portfolio include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The firm, incorporated in 2021, was initially named DRVW 2022 plc before rebranding to Haleon plc in February 2022. Its corporate headquarters are located in Brentford, United Kingdom.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free